Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.58 EUR
Change Today +0.022 / 0.86%
Volume 7.6K
AAQ On Other Exchanges
Symbol
Exchange
Xetra
Xetra
As of 3:35 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

aap implantate (AAQ) Snapshot

Open
€2.54
Previous Close
€2.55
Day High
€2.60
Day Low
€2.52
52 Week High
07/3/14 - €3.50
52 Week Low
10/29/14 - €2.05
Market Cap
79.0M
Average Volume 10 Days
21.6K
EPS TTM
€-0.04
Shares Outstanding
30.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AAP IMPLANTATE (AAQ)

Related News

No related news articles were found.

aap implantate (AAQ) Related Businessweek News

No Related Businessweek News Found

aap implantate (AAQ) Details

aap Implantate AG, a medical device company, researches, develops, manufactures, and sells implants, medical instruments, bone cements, and replacement materials for use in orthopedic procedures in Germany and internationally. It provides LOQTEQ, an anatomical angular stable plating system for compressing fractures with angular stable locking screws; and fragment set comprising T, L, quarter tubular, and reconstruction plates, as well as cortical and cancellous screws. It also offers cannulated screws for the treatment of hand and foot fracture; AcroPlate, which is used for the treatment of AC joint injuries; and autodynamic plating systems for secure fracture stabilization. In addition, the company provides a range of bone cements and accessories for application in arthroplasty, vertebroplasty, and kyphoplasty; and collagen fleeces for ambulant and stationary tissue care. Further, it offers bone substitutes that includes Artosal, a synthetic osteoconductive bone substitute; Cerabone, a ceramic bone substitute; OsteoCem, a calcium phosphate cement; Osnatal, a human bone allograft; and PerOssal, a synthetic bone substitute and carrier material. The company sells its products through its direct sales force, and distribution partners, as well as through license agreements with OEM partners. aap Implantate AG is headquartered in Berlin, Germany.

199 Employees
Last Reported Date: 03/31/15

aap implantate (AAQ) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €381.0K
Chief Finance Officer and Member of the Manag...
Total Annual Compensation: €260.0K
Compensation as of Fiscal Year 2013.

aap implantate (AAQ) Key Developments

AAP Implantate AG, 2014 Earnings Call, Apr 07, 2015

AAP Implantate AG, 2014 Earnings Call, Apr 07, 2015

AAP Eyes Acquisitions

AAP Implantate AG (XTRA:AAQ) is seeking acquisitions. AAP continues to screen the market for potential smaller bolt-on acquisition targets.

AAP Implantate AG Announces Consolidated Audited Earnings Results for the Year 2014; Provides Earnings Guidance for the First Quarter and Full Year of 2015

AAP Implantate AG announced consolidated audited earnings results for the year 2014. For the year, the company reported sales revenue of EUR 29.8 million against EUR 25.8 million a year ago. Total sales were EUR 31.6 million against EUR 40.0 million a year ago. Excluding special effects, EBITDA continued operations (normalized) were EUR 1.4 million against EUR 0.4 million a year ago. The positive sales development in the reporting period was particularly driven by the trauma business. EBITDA was EUR 2.3 million against EUR 7.4 million a year ago. Total LBIT was EUR 0.1 million against EUR 2.1 million a year ago. The company announced that for the financial year 2015 it aims sales growth to a value of between EUR 33 million and EUR 35 million, EBITDA of between EUR 2.5 million and EUR 3.5 million. For the first quarter of 2015, company expects sales of between EUR 6.5 million and EUR 7.0 million. For EBITDA the company anticipates a value of between EUR 0.5 million and EUR 0.1 million for the first three months of the current financial year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AAQ:GR €2.58 EUR +0.022

AAQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AAQ.
View Industry Companies
 

Industry Analysis

AAQ

Industry Average

Valuation AAQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book 1.6x
Price/Cash Flow 38.0x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AAP IMPLANTATE, please visit www.aap.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.